JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (6): 809-814.doi: 10.3969/j.issn.1674-8115.2021.06.018

• Review • Previous Articles     Next Articles

Research progress of RNA m6A methylation modification in regulating tumor function and its inhibitors

Ya-juan HAO1,2(), Ying-bin LIU2,3()   

  1. 1.Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Research Center of Biliary Tract Disease, Shanghai 200092, China
    2.Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China
    3.Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Oncogenes and Related Genes; Shanghai Cancer Institute, Shanghai 200120, China
  • Online:2021-06-28 Published:2021-06-29
  • Contact: Ying-bin LIU;
  • Supported by:
    Rising-Star Program of Science and Technology Committee of Shanghai Municipality(19QA1405900);National Natural Science Foundation of China(31701124);Shanghai Key Laboratory Project of Science and Technology Committee of Shanghai Municipality(17DZ2260200)


RNA modifications play an important role in physiology and pathology. N6-methyladenine (m6A) has been identified as a prevalent methylation modification on eukaryotic RNAs. RNA m6A can be reversible. In recent years, abnormal expression of the RNA m6A modification enzymes and binding proteins have been found in tumors, and they promote or inhibit the tumor progression by altering the mRNA m6A modification levels of the target genes. This paper reviews the important functions of FTO α-ketoglutarate dependent dioxygenase, AlkB homolog 5 (ALKBH5) and methyltransferase like 3 (METTL3) in a variety of tumors, and also reports their small molecule inhibitors.

Key words: RNA N6-methyladenine (m6A), tumor, inhibitor, FTO α-ketoglutarate dependent dioxygenase

CLC Number: